303 related articles for article (PubMed ID: 23004926)
1. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
[TBL] [Abstract][Full Text] [Related]
2. [Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis].
Hund M; Sinkgraven R; Rzany B
J Dtsch Dermatol Ges; 2004 May; 2(5):343-9. PubMed ID: 16281522
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin A for axillary hyperhidrosis (excessive sweating).
Heckmann M; Ceballos-Baumann AO; Plewig G;
N Engl J Med; 2001 Feb; 344(7):488-93. PubMed ID: 11172190
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
Naumann M; Lowe NJ; Kumar CR; Hamm H;
Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
[TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
[TBL] [Abstract][Full Text] [Related]
8. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial.
Ibrahim O; Kakar R; Bolotin D; Nodzenski M; Disphanurat W; Pace N; Becker L; West DP; Poon E; Veledar E; Alam M
J Am Acad Dermatol; 2013 Jul; 69(1):88-95. PubMed ID: 23591103
[TBL] [Abstract][Full Text] [Related]
9. Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis.
Paul A; Kranz G; Schindl A; Kranz GS; Auff E; Sycha T
Lasers Surg Med; 2010 Mar; 42(3):211-4. PubMed ID: 20333738
[TBL] [Abstract][Full Text] [Related]
10. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
[TBL] [Abstract][Full Text] [Related]
11. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a new aluminium salt thermophobic foam in the treatment of axillary and palmar primary hyperhidrosis: a pilot exploratory trial.
Innocenzi D; Lupi F; Bruni F; Frasca M; Panetta C; Milani M
Curr Med Res Opin; 2005 Dec; 21(12):1949-53. PubMed ID: 16368045
[TBL] [Abstract][Full Text] [Related]
13. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
14. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
[TBL] [Abstract][Full Text] [Related]
15. Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival.
Campanati A; Sandroni L; Gesuita R; Giuliano A; Giuliodori K; Marconi B; Ganzetti G; Offidani A
J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):917-21. PubMed ID: 21054569
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis.
Talarico-Filho S; Mendonça DO Nascimento M; Sperandeo DE Macedo F; DE Sanctis Pecora C
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S44-50. PubMed ID: 17241414
[TBL] [Abstract][Full Text] [Related]
17. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F
Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
[TBL] [Abstract][Full Text] [Related]
19. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study.
Heckmann M; Plewig G;
Arch Dermatol; 2005 Oct; 141(10):1255-9. PubMed ID: 16230563
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up.
Caplin D; Austin J
J Drugs Dermatol; 2014 Apr; 13(4):449-56. PubMed ID: 24719065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
